Εosinophilic Chronic Obstructive Pulmonary Disease. What Do We Know So Far? [0.03%]
关于嗜酸细胞性慢性阻塞性肺病，我们目前了解多少？
Konstantinos Bartziokas,Andriana I Papaioannou,Nikoletta Rovina et al.
Konstantinos Bartziokas et al.
The latest advances in asthma treatment have highlighted the significance of eosinophilia and the possible role of some pro-eosinophilic mediators, like interleukins (IL) IL-5, IL-4/IL-13, and IL-33 in the disease's pathogenesis. Considerin...
A Retrospective Study Evaluating Asthma Control in Patients on Fluticasone Propionate/Salmeterol Proactive Regular Dosing with a History of Uncontrolled Asthma [0.03%]
回顾性研究：评估既往难以控制哮喘患者的福莫特罗丙酸酯/氟替卡松主动规律给药的疗效
Ahmad Izuanuddin Ismail,Irfhan Ali Hyder Ali,Chee Kuan Wong et al.
Ahmad Izuanuddin Ismail et al.
Introduction: The MERIT study in Malaysia is a real-world retrospective, observational, multicenter study that evaluated asthma control in patients with uncontrolled asthma who were switched from as-needed (pro re nata [P...
Long-Term Safety and Efficacy of Macitentan in Inoperable Chronic Thromboembolic Pulmonary Hypertension: Results from MERIT and its Open-Label Extension [0.03%]
马西替坦治疗不可手术慢性血栓栓塞性肺动脉高压的长期安全性和疗效：来自MERIT研究及其开放标签延展研究的结果
Nick H Kim,Andrea M D&#x;Armini,Luke S Howard et al.
Nick H Kim et al.
Introduction: Evidence for use of pulmonary arterial hypertension targeted-therapies in patients with chronic thromboembolic pulmonary hypertension (CTEPH) is limited. In MERIT-1, the endothelin receptor antagonist macite...
Do Antidepressants Worsen COPD Outcomes in Depressed Patients with COPD? [0.03%]
抗抑郁药物会恶化COPD合并抑郁症患者的预后吗？
Alan G Kaplan
Alan G Kaplan
The coexistence of depression with chronic obstructive pulmonary disease (COPD) has been associated with poorer outcomes. Studies have questioned the safety of antidepressants in patients with COPD. This review shows the potential relations...
Perspectives on Drug Product Design Among Patients with Lung Cancer in the United Kingdom [0.03%]
英国肺癌患者对药物产品设计的看法
Joshua R Coulter,Louis Edward Baig,Amy Antipas et al.
Joshua R Coulter et al.
Introduction: The use of oral anticancer medications has become more prevalent in cancer therapy. This is particularly the case in the management of advanced non-small cell lung cancer (NSCLC). However, when the treatment...
Efficacy of High Flow Nasal Cannula in the Treatment of Patients with COVID-19 with Acute Respiratory Distress Syndrome: Results of Single Centre Study in Vietnam [0.03%]
高流量鼻导管在COVID-19急性呼吸窘迫综合征患者治疗中疗效：越南单中心研究结果
Sy Duong-Quy,Duc Huynh-Truong-Anh,Tram Tang-Thi-Thao et al.
Sy Duong-Quy et al.
Introduction: Most hospitalized patients required invasive or non-invasive ventilation and High Flow Nasal Cannula (HFNC). Therefore, this study was conducted to describe the characteristics of patients with severe Corona...
Expert Panel Consensus Recommendations for Allergic Rhinitis in Patients with Asthma in India [0.03%]
印度哮喘患者过敏性鼻炎专家共识意见推荐
R Narasimhan,Sitesh Roy,Meghanadh Koralla et al.
R Narasimhan et al.
Allergic rhinitis and asthma are commonly coexisting conditions, significantly impacting patient health and quality of life. Despite their interrelation, diagnosing allergic rhinitis in patients with asthma remains challenging, leading to u...
Survival Outcomes in US Medicare Patients with Non-Cystic Fibrosis Bronchiectasis by Rate of Baseline Exacerbations [0.03%]
美国医疗保险患者支气管扩张的生存结果及其稳定时期的加重率
Joseph Feliciano,Benjamin Lewing,Maitreyee Mohanty et al.
Joseph Feliciano et al.
Introduction: There are limited real-world data on outcomes in patients with non-cystic fibrosis bronchiectasis (NCFBE). This study assessed clinical characteristics and survival in patients with NCFBE by baseline exacerb...
Patient Profile-Based Management with Nintedanib in Patients with Idiopathic Pulmonary Fibrosis [0.03%]
基于患者特征的特发性肺纤维化患者尼达尼布管理策略分析
Vinod K Viswanathan,Aloke G Ghoshal,Anant Mohan et al.
Vinod K Viswanathan et al.
A severe and progressive interstitial lung disease (ILD) known as idiopathic pulmonary fibrosis (IPF) has an unknown etiology with poorly defined mechanisms of development. Among the currently prescribed pharmacological interventions for IP...
Comparison of Reporting Quality in National Cystic Fibrosis Patient Registries: Implications for Identifying Use of Novel CFTR Modulators [0.03%]
囊性纤维化国家患者登记报告质量的比较：识别新型CFTR调控剂使用情况的影响
Owen W Tomlinson,Philip Mitchelmore,Craig A Williams
Owen W Tomlinson
Introduction: Advances in development of cystic fibrosis transmembrane conductance regulator modulator (CFTRm) therapies mean that now people who are heterozygous (instead of having to be homozygous) for the common F508de...